Meeting
2012 ASCO Annual Meeting
Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer.
Authors
Salvia Sanjay Jain
New York University School of Medicine, New York, NY
Salvia Sanjay Jain , Yan G. Makeyev , Franco Muggia , James L. Speyer , John Patrick Curtin , Stephanie V. Blank , Leslie R. Boyd , Bhavana Pothuri , David Fishman , Xiaochun Li , Judith D. Goldberg , Amy Tiersten
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01091259
Citation
J Clin Oncol 30, 2012 (suppl; abstr 5016)
DOI
10.1200/jco.2012.30.15_suppl.5016
Abstract #
5016
Poster Bd #
5
Abstract Disclosures
Similar Posters
Poster
2014 ASCO Annual Meeting
A phase II trial on the combination of bevacizumab and irinotecan in recurrent ovarian cancer.
First Author: Huichung Tina Ling
Poster
2018 Gastrointestinal Cancers Symposium
Phase II study of FOLFIRI + ramucirumab with recurrent colorectal cancer refractory to adjuvant chemotherapy with oxaliplatin / fluoropyrimidine (RAINCLOUD).
First Author: Naotoshi Sugimoto
Poster
2015 ASCO Annual Meeting
A phase Ib/II trial with expansion of patients at the MTD trial of olaparib plus weekly (metronomic) carboplatin and paclitaxel in relapsed ovarian cancer patients.
First Author: Saul E. Rivkin
Poster
2014 ASCO Annual Meeting
Phase II trial of oxaliplatin and 5-FU in patients (pts) with platinum-resistant recurrent (PRR) ovarian carcinoma (OVCA).
First Author: Joseph N. Kerger